

LEON KIRCIK, MD, FAAD BOARD OF DIRECTOR

SUB-SPECIALTY(S)

Medical: 80%
Surgical: 20%

ALLOCATION OF TIME

Academic Practice: 4%
Clinical: 4
Private Practice: 96%
Clinical: 90%
Administrative: 6%



EDUCATION

University of Wisconsin
Mohs Micrographic Surgery & Cutaneous Oncology Fellowship

SUNY Buffalo Dermatology Residency

New York Medical College
Westchester County Medical Center
Internal Medicine, Internship

SUNY Brooklyn - M.D. May 1989

New York University, New York, New York
Washington Square University College
Bachelor of Arts - Chemistry, May 1985

CERTIFICATION

ABD: 1993, 2003, 2013

AREAS OF INTEREST

Clinical Research

ACADEMIC AFFILIATIONS

Indiana University School of Medicine, Indianapolis
Icahn School of Medicine at Mount Sinai, New York-Clinical Professor
of Dermatology

CLINICAL AFFILIATIONS

Physicians Skin Care, DermResearch, Skin Sciences, Louisville

PRESENT ACADEMIC POSITION

Clinical Associate Professor

ACADEMY INVOLVEMENT

4/1/2017 – 4/1/2020 Member Communication Committee
4/1/2015 – 4/1/2018 International Affairs Committee
4/1/2016 – 11/5/2016 Coding and Reimbursement Task Force
11/5/2016 – 4/1/2018 Coding and Reimbursement Committee
3/1/2012 – 4/1/2016 Business and Operation Support Task Force

ELECTED AND APPOINTED POSITIONS

National Psoriasis Foundation Medical Advisory Board
ASDS
Development Industry Relations Work Group
Policy Priorities Work Group
Membership Work Group
Media and Public Relations Work Group
Consumer Research Work Group

HONORS AND AWARDS

Stars of Academy, AOA, Phi Beta Kappa

PUBLICATIONS/PRESENTATIONS

150+ Publications 200+ Presentations

Hashim P, Lebwohl M, Kircik L, Secukinumab: Long-Term Safety and Efficacy in Psoriasis
J Drugs Dermatol 2017;16(8) suppl 1:s115-117

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J., Puig L, Papp L, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, et al. Phase 3 studies comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med 2015;373:1318-28

RESPONSE TO THE QUESTIONS POSED BY THE NOMINATING COMMITTEE

1. What is your primary reason for running for the Board?

Representing our membership against external forces with one unified voice in the house of medicine, in public relations and in legislative advocacy and effecting change that will benefit all are my sole motivations to join the Board.

2. What qualities and experiences would you bring to the Board?

My experience as a young man immigrating to the USA and graduating from NYU with English acquired watching "General Hospital" and adapting to a new culture made me flexible, practical and a problem solver.

My diverse dermatology experience from caring for AIDS patients and inmates in NYC to underserved Appalachian folks and inner-city Louisville patients helped me to understand and treat all patients.

Therefore, I will successfully represent and advocate for all different groups of Academy membership with one unified voice and achieve favorable results for everyone involved.